Brief: Medicenna Presents Updated Results Of Single Agent MDNA11 Anti-Tumor Activity From Dose Escalation And Ongoing Dose Expansion Of The Phase 1/2 ABILITY-1 Study At The 2024 Annual Meeting Of The American Association For Cancer Research

Medicenna Therapeutics

09/04/2024 22:26

April 9 (Reuters) - Medicenna Therapeutics Corp
 MDNA.TO :
    * MEDICENNA PRESENTS UPDATED RESULTS OF SINGLE AGENT MDNA11
ANTI-TUMOR ACTIVITY FROM DOSE ESCALATION AND ONGOING DOSE
EXPANSION OF THE PHASE 1/2 ABILITY-1 STUDY AT THE 2024 ANNUAL
MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)
    * MEDICENNA THERAPEUTICS CORP - DURABLE STABLE DISEASE (SD)
IN 3
MELANOMA PATIENTS FOR 6 TO 18 MONTHS WITH CONCOMITANT TUMOR
SHRINKAGE
    * MEDICENNA THERAPEUTICS CORP - MDNA11 IS GENERALLY WELL
TOLERATED
WITH NO DOSE-LIMITING TOXICITIES OR VASCULAR LEAK SYNDROME
REPORTED IN ANY OF DOSE ESCALATION COHORTS
    * MEDICENNA THERAPEUTICS CORP - 100% REDUCTION OF TARGET
LESIONS
IN ONE MELANOMA AND ONE PANCREATIC CANCER PATIENT OBSERVED AMONG
4 PR TO DATE
    * MEDICENNA THERAPEUTICS - NEW SITES IN US & KOREA STARTED
ENROLMENT IN ONGOING MONOTHERAPY EXPANSION & COMBINATION
ESCALATION ARMS OF ABILITY-1 STUDY

Source text for Eikon:  ID:nGNX9PHdRK 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))